In a study published in Advanced Functional Materials, a research team from the Shanghai Institute of Materia Medica (SIMM) ...

The UK’s MHRA has approved Takeda’s Fruzaqla (fruquintinib) for metastatic colorectal cancer (CRC) in adults who have not ...

Researchers investigated the efficacy of total neoadjuvant treatment followed by nonoperative management in patients with locally advanced rectal cancer.

Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients ...

CRC is an abnormal growth of cells that begins in a part of the large intestine called the colon. When the cancer is ...

The study has 3 components: an SLI portion, a phase 3 randomization, and a second randomization labeled as cohort 3. The SLI includes 2 cohorts: EC plus FOLFIRI (cohort 1) and EC plus 5-fluorouracil, ...

Secondary end points included cCR rate and organ preservation rate in patients who received NOM. Induction therapy began ...

A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal ...

Despite improvement in pathologic complete response with preoperative chemoradiation, the benefit did not extend to overall ...

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed amivantamab combined with chemotherapy (mFOLFOX6 [FOLFOX] or ...

NuCana plc is a clinical-stage biopharmaceutical company dedicated to enhancing cancer treatments through its ProTide technology. This innovative approach transforms conventional chemotherapy agents, ...